Junzo Hamanishi

List of Publications by Year
in descending order

125 papers	8,226 citations	126907 33 h-index	49909 87 g-index
130 all docs	130 docs citations	130 times ranked	12555 citing authors

#	Article	IF	Citations
1	Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3360-3365.	7.1	1,308
2	Safety and Antitumor Activity of Antiâ€“PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology, 2015, 33, 4015-4022.	1.6	924
3	IFN-Î³ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. British Journal of Cancer, 2015, 112, 1501-1509.	6.4	533
4	Cancer immunotherapies targeting the PD-1 signaling pathway. Journal of Biomedical Science, 2017, 24, 26.	7.0	501
5	Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-ÎºB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. Cancer Research, 2015, 75, 5034-5045.	0.9	439
6	Host expression of PD-L1 determines efficacy of PD-L1 pathway blockadeâ€“mediated tumor regression. Journal of Clinical Investigation, 2018, 128, 805-815.	8.2	423
7	Dual Faces of IFNÎ³ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity. Clinical Cancer Research, 2016, 22, 2329-2334.	7.0	309
8	Contents of Endometriotic Cysts, Especially the High Concentration of Free Iron, Are a Possible Cause of Carcinogenesis in the Cysts through the Iron-Induced Persistent Oxidative Stress. Clinical Cancer Research, 2008, 14, 32-40.	7.0	259
9	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. International Journal of Clinical Oncology, 2016, 21, 462-473.	2.2	255
10	Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells. Clinical Cancer Research, 2017, 23, 587-599.	7.0	213
11	Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nature Communications, 2018, 9, 1685.	12.8	211
12	PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction. Clinical Cancer Research, 2013, 19, 1363-1374.	7.0	196
13	Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene, 2010, 29, 1741-1752.	5.9	165
14	Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunology, Immunotherapy, 2009, 58, 641-652.	4.2	144
15	Tumor Immune Microenvironment during Epithelialâ€“Mesenchymal Transition. Clinical Cancer Research, 2021, 27, 4669-4679.	7.0	138
16	VISTA expressed in tumour cells regulates T cell function. British Journal of Cancer, 2019, 120, 115-127.	6.4	133
17	Immune checkpoint inhibition in ovarian cancer. International Immunology, 2016, 28, 339-348.	4.0	122
18	Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks. American Journal of Pathology, 2017, 187, 2246-2258.	3.8	104

#	Article	IF	Citations
19	Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. Gynecologic Oncology, 2018, 151, 381-389.	1.4	99
20	Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). Journal of Clinical Oncology, 2021, 39, 3671-3681.	1.6	84
21	Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes. American Journal of Pathology, 2016, 186, 1103-1113.	3.8	71
22	The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clinical Immunology, 2011, 141, 338-347.	3.2	70
23	STAT1 Drives Tumor Progression in Serous Papillary Endometrial Cancer. Cancer Research, 2014, 74, 6519-6530.	0.9	66
24	The activated transforming growth factorâ€beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. International Journal of Cancer, 2012, 130, 20-28.	5.1	62
25	Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment. British Journal of Cancer, 2020, 122, 778-788.	6.4	61
26	Hepatocyte nuclear factorâ€1Î² (HNFâ€1Î²) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma. Molecular Carcinogenesis, 2015, 54, 35-49.	2.7	57
27	Oct4 Expression in Immature Teratoma of the Ovary. American Journal of Surgical Pathology, 2010, 34, 1842-1848.	3.7	51
28	B7-H3 Suppresses Antitumor Immunity via the CCL2â€“CCR2â€“M2 Macrophage Axis and Contributes to Ovarian Cancer Progression. Cancer Immunology Research, 2022, 10, 56-69.	3.4	49
29	CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. JCI Insight, 2022, 7, .	5.0	48
30	Metabolic alterations caused by HNF1Î² expression in ovarian clear cell carcinoma contribute to cell survival. Oncotarget, 2015, 6, 26002-26017.	1.8	47
31	Activated Local Immunity by CCL19-Transduced Embryonic Endothelial Progenitor Cells Suppresses Metastasis of Murine Ovarian Cancer. Stem Cells, 2009, 28, N/A-N/A.	3.2	42
32	Ovarian clear cell carcinoma as a stress-responsive cancer: Influence of the microenvironment on the carcinogenesis and cancer phenotype. Cancer Letters, 2011, 310, 129-133.	7.2	37
33	GPR54 Is a Target for Suppression of Metastasis in Endometrial Cancer. Molecular Cancer Therapeutics, 2011, 10, 580-590.	4.1	37
34	Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression. Modern Pathology, 2009, 22, 373-384.	5.5	34
35	The BMP signaling pathway leads to enhanced proliferation in serous ovarian cancer-A potential therapeutic target. Molecular Carcinogenesis, 2016, 55, 335-345.	2.7	33
36	Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles. Gynecologic Oncology, 2016, 141, 49-56.	1.4	33

#	Article	IF	Citations
37	Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer.. Journal of Clinical Oncology, 2014, 32, 5511-5511.	1.6	33
38	Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Science, 2010, 101, 2658-2663.	3.9	32
39	Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application. International Journal of Clinical Oncology, 2016, 21, 456-461.	2.2	29
40	Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma. Scientific Reports, 2019, 9, 10144.	3.3	29
41	Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer. Oncotarget, 2016, 7, 47620-47636.	1.8	28
42	Ileal perforation and massive intestinal haemorrhage from endometriosis in pregnancy: case report and literature review. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 170, 20-24.	1.1	27
43	Pyomayoma during pregnancy: A case report and review of the literature. Journal of Obstetrics and Gynaecology Research, 2013, 39, 383-389.	1.3	27
44	Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification. Medical Molecular Morphology, 2019, 52, 52-59.	1.0	25
45	Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma. Oncotarget, 2016, 7, 54758-54770.	1.8	25
46	Endovascular trophoblast expresses CD59 to evade complement-dependent cytotoxicity. Molecular and Cellular Endocrinology, 2019, 490, 57-67.	3.2	23
47	Invasion of uterine cervical squamous cell carcinoma cells is facilitated by locoregional interaction with cancer-associated fibroblasts via activating transforming growth factor-beta. Gynecologic Oncology, 2015, 136, 104-111.	1.4	21
48	Menstrual cyclic change of metastin/GPR54 in endometrium. Medical Molecular Morphology, 2015, 48, 76-84.	1.0	20
49	Immortalized ovarian surface epithelial cells acquire tumorigenicity by Acrogranin gene overexpression. Oncology Reports, 2007, 17, 329-33.	2.6	20
50	Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. JCO Precision Oncology, 2022, , .	3.0	18
51	Cervical clamp with ring forceps to prevent prolapse of an intrauterine balloon in the management of postpartum hemorrhage. Journal of Obstetrics and Gynaecology Research, 2013, 39, 733-737.	1.3	17
52	Radiomic machine learning for pretreatment assessment of prognostic risk factors for endometrial cancer and its effects on radiologists' decisions of deep myometrial invasion. Magnetic Resonance Imaging, 2022, 85, 161-167.	1.8	17
53	Durable tumor remission in patients with platinum-resistant ovarian cancer receiving nivolumab.. Journal of Clinical Oncology, 2015, 33, 5570-5570.	1.6	16
54	Remote solid cancers rewire hepatic nitrogen metabolism via host nicotinamide-N-methyltransferase. Nature Communications, 2022, 13, .	12.8	16

#	Article	IF	Citations
55	A case of successful management of maternal septic shock with multiple organ failure following amniocentesis at midgestation. Journal of Obstetrics and Gynaecology Research, 2002, 28, 258-261.	1.3	15
56	Treatment decision-making for post-partum hemorrhage using dynamic contrast-enhanced computed tomography. Journal of Obstetrics and Gynaecology Research, 2014, 40, 67-74.	1.3	15
57	PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma. Cancer Science, 2021, 112, 4627-4640.	3.9	15
58	Tertiary lymphoid structures are associated with favorable survival outcomes in patients with endometrial cancer. Cancer Immunology, Immunotherapy, 2022, 71, 1431-1442.	4.2	15
59	Recurrence of a carcinoid tumor of the ovary 13 years after the primary surgery: A case report. Oncology Letters, 2013, 6, 1241-1244.	1.8	14
60	Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum. BMC Cancer, 2017, 17, 580.	2.6	14
61	Antitumor Effect of Nivolumab on Subsequent Chemotherapy for Platinum-Resistant Ovarian Cancer. Oncologist, 2018, 23, 1382-1384.	3.7	14
62	Malignant transformation of mature cystic teratoma of the ovary including three cases occurring during follow-up period. Oncology Reports, 2008, , .	2.6	13
63	Distinguishing primary from secondary mucinous ovarian tumors: an algorithm using the novel marker DPEP1. Modern Pathology, 2011, 24, 267-276.	5.5	13
64	A novel diagnostic criterion for lymph node metastasis in cervical cancer using multi-detector computed tomography. Gynecologic Oncology, 2013, 131, 701-707.	1.4	13
65	Clinical approaches to treating papillary squamous cell carcinoma of the uterine cervix. BMC Cancer, 2014, 14, 784.	2.6	12
66	Magnetic resonance imaging findings and prognosis of gastric-type mucinous adenocarcinoma (minimal deviation adenocarcinoma or adenoma malignum) of the uterine corpus: Two case reports. Molecular and Clinical Oncology, 2016, 4, 699-704.	1.0	12
67	Novel subtype of atonic postpartum hemorrhage: dynamic computed tomography evaluation of bleeding characteristics and the uterine cavity. Journal of Maternal-Fetal and Neonatal Medicine, 2020, 33, 3286-3292.	1.5	12
68	Malignant transformation of mature cystic teratoma of the ovary including three cases occurring during follow-up period. Oncology Reports, 2008, 19, 705-11.	2.6	12
69	Utilization of genomic signatures to identify highâ€efficacy candidate drugs for chemorefractory endometrial cancers. International Journal of Cancer, 2013, 133, 2234-2244.	5.1	11
70	The effect of the type of dietary protein on the development of ovarian cancer. Oncotarget, 2018, 9, 23987-23999.	1.8	11
71	Acquisition of a side population fraction augments malignant phenotype in ovarian cancer. Scientific Reports, 2019, 9, 14215.	3.3	11
72	Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients. BMC Cancer, 2015, 15, 739.	2.6	10

#	Article	IF	Citations
73	Groin lymph node detection and sentinel lymph node biopsy in vulvar cancer. Journal of Gynecologic Oncology, 2016, 27, e57.	2.2	10
74	Prognostic utility of FDG PET/CT in advanced ovarian, fallopian and primary peritoneal high-grade serous cancer patients before and after neoadjuvant chemotherapy. Annals of Nuclear Medicine, 2020, 34, 128-135.	2.2	10
75	Immortalized ovarian surface epithelial cells acquire tumorigenicity by Acrogranin gene overexpression. Oncology Reports, 2007, , .	2.6	9
76	Serial magnetic resonance imaging of placenta percreta with bladder involvement during pregnancy and postpartum: A case report. Journal of Obstetrics and Gynaecology Research, 2013, 39, 359-363.	1.3	9
77	Hysteroscopic morphological pattern reflects histological grade of endometrial cancer. Journal of Obstetrics and Gynaecology Research, 2019, 45, 1479-1487.	1.3	9
78	Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. JCO Precision Oncology, 2021, 5, 1270-1280.	3.0	9
79	The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients. Journal of Gynecologic Oncology, 2019, 30, e100.	2.2	9
80	Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer. Journal of Gynecologic Oncology, 2021, 32, e16.	2.2	8
81	Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma. Cancers, 2021, 13, 2413.	3.7	8
82	Embryogenesis of fused umbilical arteries in human embryos. American Journal of Obstetrics and Gynecology, 2005, 193, 1709-1715.	1.3	7
83	Intractable recurrent cervical cancer with pelvic bone involvement successfully treated with external hemipelvectomy. Journal of Obstetrics and Gynaecology Research, 2008, 34, 112-116.	1.3	7
84	UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study. BMC Cancer, 2020, 20, 729.	2.6	7
85	Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer. Journal of Gynecologic Oncology, 2021, 32, e21.	2.2	7
86	Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: utilization for ovarian cancer treatment. Oncology Reports, 2008, 19, 505-15.	2.6	7
87	Clinical Management of Ovarian Endometriotic Cyst (Chocolate Cyst): Diagnosis, Medical Treatment, and Minimally Invasive Surgery. Current Obstetrics and Gynecology Reports, 2012, 1, 16-24.	0.8	6
88	Phosphorylation of STAT1 serine 727 enhances platinum resistance in uterine serous carcinoma. International Journal of Cancer, 2019, 145, 1635-1647.	5.1	6
89	Bevacizumab-associated events in Japanese women with cervical cancer: a multi-institutional survey of Obstetrical Gynecological Society of Kinki district, Japan. International Journal of Clinical Oncology, 2021, 26, 598-605.	2.2	6
90	Spontaneous regression of congenital cystic adenomatoid malformation of the lung: Longitudinal examinations by magnetic resonance imaging. Congenital Anomalies (discontinued), 2005, 45, 157-160.	0.6	5

#	Article	IF	Citations
91	Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer. Journal of International Medical Research, 2016, 44, 346-356.	1.0	5
92	Sebaceous carcinoma of the vulva treated with sentinel lymph node biopsy: a case report and literature review. International Cancer Conference Journal, 2021, 10, 239-243.	0.5	5
93	Transverse fundal uterine incision for delivery of extremely low birth-weight infants. Journal of Maternal-Fetal and Neonatal Medicine, 2014, 27, 1285-1287.	1.5	4
94	Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma. Journal of Gynecologic Oncology, 2017, 28, e62.	2.2	4
95	Oncofertility care in young women and the outcomes of pregnancy over the last 5Âyears. Future Science OA, 2021, 7, FSO680.	1.9	4
96	A 36â€‰kg Giant Ovarian Fibroma with Meigs Syndrome: A Case Report and Literature Review of Extremely Giant Ovarian Tumor. Case Reports in Obstetrics and Gynecology, 2021, 2021, 1-8.	0.3	4
97	Fertility preservation of polypoid endometriosis: Case series and literature review. Journal of Obstetrics and Gynaecology Research, 2021, , .	1.3	4
98	Suppression of Metastatic Murine Ovarian Cancer Cells by Transduced Embryonic Progenitor Cells. Hormones and Cancer, 2010, 1, 291-296.	4.9	3
99	Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy. Medical Science Monitor, 2017, 23, 826-833.	1.1	3
100	Two Cases of Ectopic Pregnancy Mimicking Gestational Trophoblastic Disease. Case Reports in Obstetrics and Gynecology, 2020, 2020, 1-4.	0.3	3
101	Low-Grade Endometrial Stromal Sarcoma with a Nodule-in-Nodule Appearance in Preoperative Magnetic Resonance Images. Case Reports in Obstetrics and Gynecology, 2020, 2020, 1-7.	0.3	3
102	Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer. Scientific Reports, 2021, 11, 11427.	3.3	3
103	Tight systolic blood pressure control early in pregnancy improves pregnancy outcomes in women with chronic hypertension. Hypertension Research in Pregnancy, 2019, 7, 75-81.	0.2	3
104	Polarity switching of ovarian cancer cell clusters via <scp>SRC</scp> family kinase is involved in the peritoneal dissemination. Cancer Science, 2022, 113, 3437-3448.	3.9	3
105	Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: Utilization for ovarian cancer treatment. Oncology Reports, 0, , .	2.6	2
106	Intracervical elastomeric sealant in an ex vivo model. Journal of Maternal-Fetal and Neonatal Medicine, 2021, 34, 1109-1111.	1.5	2
107	Immunology and Immunotherapy in Ovarian Cancer. Comprehensive Gynecology and Obstetrics, 2017, , 225-242.	0.0	2
108	Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program. Vaccines, 2022, 10, 188.	4.4	2

#	Article	IF	Citations
109	Immunosuppressive tumor microenvironment in Uterine Serous Carcinoma via CCL7 signal with myeloid-derived suppressor cells. Carcinogenesis, 2022, , .	2.8	2
110	Successful management of intraoperative haemorrhage during emergency cervical cerclage using balloon tamponade. Journal of Obstetrics and Gynaecology, 2017, 37, 523-524.	0.9	1
111	An experience of second-trimester anhydramnios salvaged by single amnioinfusion. Journal of Medical Ultrasonics (2001), 2018, 45, 525-527.	1.3	1
112	Specific gene signatures and oligo clonal expansion of b cell repertoire with responders of anti-PD-1 antibody, nivolumab for ovarian cancer: Novel predictive biomarkers.. Journal of Clinical Oncology, 2016, 34, 5513-5513.	1.6	1
113	Reply to D.-C. Mo et al. Journal of Clinical Oncology, 2022, 40, 523-524.	1.6	1
114	A case of complete hydatidiform mole with coexistent fetus developing hypertension and acute heart failure. Hypertension Research in Pregnancy, 2017, 5, 20-23.	0.2	0
115	Feasibility of laparoscopic surgery for obese patients with uterine corpus cancer. Japanese Journal of Gynecologic and Obstetric Endoscopy, 2018, 34, 159-164.	0.0	0
116	Three cases of seromucinous carcinoma of the ovary arising in endometriotic cysts. International Cancer Conference Journal, 2021, 10, 46-53.	0.5	0
117	A Case of Torsion in an Otherwise-Normal Ovary with a Giant Hematosalpinx Larger than Enlarged Ovary: Utilization of Diagnostic Laparoscopy for the Accurate Diagnosis. Case Reports in Obstetrics and Gynecology, 2021, 2021, 1-5.	0.3	0
118	A Novel Direct Approach to the Deep Uterine Vein in Laparoscopic Radical Hysterectomy. Journal of Minimally Invasive Gynecology, 2021, 28, 1444-1445.	0.6	0
119	Superradical Hysterectomy for Cervical Cancer as an Alternative to the Usual Okabayashi-Type Radical Hysterectomy. The Surgery Journal, 2021, 7, S108-S114.	0.7	0
120	Abstract A25: Dysregulation of MYC via STAT1 promotes tumor progression in serous papillary endometrial cancer. , 2015, , .		0
121	Immunotherapy for Gynecologic Cancer. Comprehensive Gynecology and Obstetrics, 2017, , 69-85.	0.0	0
122	Laparoscopic conservative surgery for bilateral massive ovarian edema presenting with hemoperitoneum. Japanese Journal of Gynecologic and Obstetric Endoscopy, 2019, 35, 119-122.	0.0	0
123	Breakthrough of Cancer Therapies Targeting PD-1 Signal Pathway. Trends in the Sciences, 2019, 24, 2_20-2_24.	0.0	0
124	Feasibility of Laparoscopic Para-Aortic Lymphadenectomy for Locally Advanced Cervical Cancer. Journal of the Society of Laparoendoscopic Surgeons, 2022, 26, e2021.00096.	1.1	0
125	Development of healthy lifestyle consciousness index for gynecological cancer patients. Supportive Care in Cancer, 0, , .	2.2	0